Objectives: To test the hypothesis that atomoxetine is noninferior to methylphenidate in improving Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms.

• 目的：验证经过约8周的双盲治疗后，托莫西汀对注意缺陷多动障碍（简称ADHD）症状的改善不亚于哌甲酯。